Current stock page

Catalysts

RLAY Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

RLAYRelay Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$18.09+$0.01 (+0.06%)

Latest quote

  • Momentum
    76
  • Value
    37
  • Quality
    47
  • Risk resilience
    52
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 25, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 56/100

Momentum 76/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 30.52%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 76/100AIQ Edge 5/10 In Line With Peers
Beat rate
63%
5 of 8 reported periods
Average surprise
+4.5%
Across covered historical reports
Latest result
+6.7%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—-$0.40-$0.37+6.7%$1.62M—
Aug 6, 2026—-$0.39-$0.41-4.8%$960K$350K
May 5, 2026—-$0.35-$0.41-17.1%$5.58M$3M
Feb 26, 2026—-$0.38-$0.32+15.8%$4.97M$7M
Nov 6, 2025—-$0.39-$0.43-10.3%$4.96M—
Aug 7, 2025—-$0.49-$0.41+16.3%$14.29K$677K
May 5, 2025—-$0.50-$0.46+8.0%$3.76M$7.68M
Feb 26, 2025—-$0.57-$0.45+21.1%$5.53M—

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
13
Buy
12-month analyst target
$29.00
+60.31% versus current price
Based on 13 analyst observations. Targets are estimates, not predictions.
Low target
$29.00
+60.31% vs latest price
Average target
$29.00
+60.31% vs latest price
High target
$29.00
+60.31% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 25, 2027

Next known earnings or reporting date.

EPS estimate-$0.38

Current analyst expectation for the upcoming report.

Revenue estimate$5.91M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score76

Where event reaction would show up first.

AIQ score56/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
13
Average target
$29.00
Target upside
60.31%
Target range
$29.00 - $29.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
seekingalpha.com · Nov 11, 2026

Relay Therapeutics, Inc. (RLAY) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Relay Therapeutics, Inc. (RLAY) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 4:30 PM ESTCompany ParticipantsSanjiv Patel - CEO,...

seekingalpha.com · Oct 16, 2026

Relay: Recent Market Excitement Ignores Reality Of Clinical Risks And Patent Cliffs

Relay is rated Hold despite a 175% rally, given overvaluation relative to a risk-adjusted fair value of $13.53 per share. Read more on RLAY stock here.

seekingalpha.com · Sep 16, 2026

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Relay Therapeutics, Inc. (RLAY) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 9:15 AM EDTCompany ParticipantsSanjiv Patel -...

seekingalpha.com · Sep 10, 2026

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Relay Therapeutics, Inc. (RLAY) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 1:30 PM EDTCompany ParticipantsPeter Rahmer - Chief...

gurufocus.com · Sep 10, 2026

Relay Therapeutics (RLAY) CFO Thomas Catinazzo Sells 17,717 Shares

Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics Inc (RLAY), sold 17,717 shares of the company on 2026-09-08, according to a recent SEC Filin

Open full news and sentiment

RLAY Catalysts FAQ

What are the next catalysts for RLAY stock?

RLAY's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move RLAY stock?

Upcoming events that could move RLAY include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could RLAY's next earnings report affect the stock?

RLAY's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive RLAY stock higher?

RLAY could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt RLAY stock?

RLAY could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.